Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmala Biotech HoldingsMDXXF +0.44%33 PS Ratio is 17.70 as of Jul. 20, 2026, which is 26% below its 10-year median of 23.96. GuruFocus rates MDXXF with a GF Score™ of 33/100 and a GF Value™ of $0.15 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 930 Biotechnology companies, Pharmala Biotech Holdings ranks worse than 62.9% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pharmala Biotech Holdings's share price is $0.1062.
Pharmala Biotech Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 was $0.01. Hence, Pharmala Biotech Holdings's PS Ratio for today is 17.70.
The historical rank and industry rank for Pharmala Biotech Holdings's PS Ratio or its related term are showing as below:
MDXXF'
s PS Ratio Range Over the Past 10 Years
Min: 4.41 Med: 23.96 Max: 395
Current: 16.74
During the past 5 years, Pharmala Biotech Holdings's highest PS Ratio was 395.00. The lowest was 4.41. And the median was 23.96.
MDXXF's PS Ratio is ranked worse than 62.9% of 930
companies
in the Biotechnology industry
Industry Median: 9.35
vs MDXXF: 16.74
During the past 5 years, Pharmala Biotech Holdings's highest 3-Year average Revenue per Share Growth Rate was 81.70% per year. The lowest was 81.70% per year. And the median was 81.70% per year.
Back to Basics: PS Ratio
Pharmala Biotech Holdings (OTCPK:MDXXF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Pharmala Biotech Holdings PS Ratio Related Terms
Pharmala Biotech Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharmala Biotech Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmala Biotech Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pharmala Biotech Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Pharmala Biotech Holdings's Share Price of today is $0.1062. Pharmala Biotech Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Pharmala Biotech Holdings (MDXXF) has a PS Ratio of 17.70 as of Jul. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pharmala Biotech Holdings and its competitors. This is 26% below median its historical median of 23.96. Over the past decade, Pharmala Biotech Holdings' PS Ratio has ranged from 4.41 to 395.00. According to the industry distribution chart, Pharmala Biotech Holdings ranks #585 out of 930 companies in the Biotechnology industry, placing it in the top 62.9%.
Is Pharmala Biotech Holdings' PS Ratio too high?
Pharmala Biotech Holdings' current PS Ratio of 17.70 is 26% below median its 10-year median of 23.96. Over the past 10 years, this metric has ranged from a low of 4.41 to a high of 395.00. The Biotechnology industry median PS Ratio is 9.35. Pharmala Biotech Holdings' value of 17.70 is 89.3% above this industry median. Based on the distribution chart, Pharmala Biotech Holdings ranks #585 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharmala Biotech Holdings has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmala Biotech Holdings ranks #585 out of 930 companies for PS Ratio. This places Pharmala Biotech Holdings in the lower half of its industry. The industry median PS Ratio is 9.35. Pharmala Biotech Holdings' value of 17.70 is 89.3% above this benchmark. Historically, Pharmala Biotech Holdings' own PS Ratio has ranged from 4.41 to 395.00 over the past decade. While the company's 10-year median is 23.96 vs. the industry median of 9.35, Pharmala Biotech Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.35, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmala Biotech Holdings's current PS Ratio of 17.70 is 89.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pharmala Biotech Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmala Biotech Holdings's current PS Ratio is 17.70, which is 26% below median its own 10-year median of 23.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 29.2% below its estimated fair value. The current PS Ratio is 17.70, which is 26% below median its 10-year median of 23.96 and 89.3% above the Biotechnology industry median of 9.35. Pharmala Biotech Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current PS Ratio is 17.70 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued.
The current stock price of $0.11 is trading 29.2% below its estimated GF Value™ of $0.15.
GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.
Key valuation signals for MDXXF:
PS Ratio: 17.70 (26% below median its 10-year median of 23.96)
GF Value™: $0.15 vs. price of $0.11 (29.2% below fair value)
Industry Position: 89.3% above the Biotechnology median (#585 of 930)
No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
33GF Score
Get the complete analysis for MDXXF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXXF has been successfully added to your 
